Latest neutropenia Stories
Multicenter trial led by St Jude Children's Research Hospital investigators may change neutropenia treatment for all childhood cancer patients.
LOS ANGELES, Sept.
Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient Population THOUSAND OAKS, Calif., May 27 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced the results of a national Harris Interactive, Inc.
Researchers have reported findings that suggest a treatment commonly used to help premature babies fight infection is ineffective.
A team of scientists has discovered a new syndrome associated with severe congenital neutropenia (SCN), a rare disorder in which children lack sufficient infection-fighting white cells, and identified the genetic cause of the syndrome: mutations in the gene Glucose-6-phosphatase, catalytic subunit 3 (G6PC3).
SAN ANTONIO, Dec.
Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data from its ongoing Phase I/II clinical trial of ispinesib were presented in a poster at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium held on September 5-7, 2008 in Washington, DC.
Celgene Corporation (Nasdaq:CELG) today announced VIDAZA (azacitidine) received expanded U.S. Food and Drug Administration (FDA) approval to reflect new overall survival achieved in the AZA-001 survival study of patients with higher-risk myelodysplastic syndromes (MDS).
Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that a GlycoPEG-GCSF Phase I clinical abstract submitted by the Company's collaborative partner, BioGeneriX AG, has been accepted for a poster presentation at the IXth World Conference on Clinical Pharmacology and Therapeutics.
RICHMOND, Va., July 10, 2008 /PRNewswire-FirstCall/ -- Insmed Inc.